XXII Stock Overview
22nd Century Group, Inc., an agricultural biotechnology company, focuses on tobacco harm reduction, reduced nicotine tobacco, and enhancing health and wellness through plant science for the life science and consumer products industries.
22nd Century Group, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$1.82|
|52 Week High||US$4.05|
|52 Week Low||US$1.42|
|1 Month Change||0.55%|
|3 Month Change||8.33%|
|1 Year Change||-54.84%|
|3 Year Change||-5.21%|
|5 Year Change||-15.35%|
|Change since IPO||40.00%|
Recent News & Updates
22nd Century GAAP EPS of -$0.06 in-line, revenue of $14.5M beats by $3.21M
22nd Century press release (NASDAQ:XXII): Q2 GAAP EPS of -$0.06 in-line. Revenue of $14.5M (+72.6% Y/Y) beats by $3.21M. The increase was due to increased contract manufacturing volumes as well as the addition of GVB Biopharma revenue for approximately half of the second quarter.
|XXII||US Tobacco||US Market|
Return vs Industry: XXII exceeded the US Tobacco industry which returned -56.8% over the past year.
Return vs Market: XXII underperformed the US Market which returned -10.1% over the past year.
|XXII Average Weekly Movement||15.3%|
|Tobacco Industry Average Movement||15.4%|
|Market Average Movement||7.7%|
|10% most volatile stocks in US Market||16.9%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: XXII is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 15% a week.
Volatility Over Time: XXII's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
22nd Century Group, Inc., an agricultural biotechnology company, focuses on tobacco harm reduction, reduced nicotine tobacco, and enhancing health and wellness through plant science for the life science and consumer products industries. It develops very low nicotine content tobacco and cigarette products under the VLN King and VLN Menthol King names; and SPECTRUM research cigarettes for use in independent clinical studies. The company has collaboration with Keygene N.V. to develop hemp/cannabis plants for exceptional cannabinoid profiles and other superior agronomic traits for medical, therapeutic, and agricultural uses, as well as other applications.
22nd Century Group, Inc. Fundamentals Summary
|XXII fundamental statistics|
Is XXII overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|XXII income statement (TTM)|
|Cost of Revenue||US$36.99m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.20|
|Net Profit Margin||-111.52%|
How did XXII perform over the long term?See historical performance and comparison